SAN FRANCISCO--(BUSINESS WIRE)--AllStripes (“Company”), a healthcare technology company dedicated to unlocking new treatments for people affected by rare disease, today announced the appointment of former Color Health executive Sherwin Chen as Chief Legal Officer and former Komodo Health executive Joe Walsh as Vice President and Head of Commercial. Both senior appointments will help the Company expand into its next phase of growth and further develop its industry-leading rare disease research platform.
Chen is an experienced counsel specializing in advising high growth digital health, biotech and healthcare companies. Prior to this role, he was General Counsel at Color Health, a population health company specializing in genetic testing and analysis, and before that he led legal teams at Roche and other leading life sciences companies. At AllStripes, Chen will apply his nearly 20 years of legal expertise to manage the legal and compliance teams. He will also advise on partnerships and corporate transactions, data privacy and regulatory compliance initiatives, and international product expansion.
“I’m excited to join the leadership team at AllStripes and look forward to putting my broad healthcare technology expertise to work to help advance new rare disease treatments,” said Sherwin Chen, Chief Legal Officer at AllStripes. “My experience with population health, therapeutics and clinical trials, and collaborating with biopharmaceutical partners and healthcare systems will be especially useful as we look to empower the rare disease community and navigate this complex, cutting-edge industry.”
AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data – all at no cost to participants. The Company collaborates with various biopharmaceutical companies and other entities on real-world evidence studies aimed to enhance clinical understanding of rare disease treatment research. AllStripes is currently partnering with more than 30 patient advocacy organizations across its 40 conditions, supporting more than 3,000 users to date.
“We are thrilled to have someone with Sherwin’s deep legal expertise in healthcare to lead our legal affairs and ensure data privacy protection, something incredibly important to us and the rare disease community that we support,” said Nancy Yu, Co-founder and CEO, AllStripes. “On top of that, we have Joe joining us to lead our commercial efforts and bring his business development experience to enable us to expand our life sciences partnerships. Both proven leaders will help us to continue to build a world-class leadership team to support our vision of transforming rare disease research.”
Walsh has significant business experience leading healthcare technology commercial teams in high growth mode. He joins AllStripes after four years as Vice President at Komodo Health, a predictive analytics platform company that has experienced rapid growth in recent years. At AllStripes, Walsh will be responsible for overseeing all aspects of the Company’s commercial go-to-market strategy and managing business development partnerships with life sciences customers.
“The rare disease community has long been underserved and new therapies and innovations are needed now more than ever,” said Joe Walsh, Vice President and Head of Commercial at AllStripes. “The progress AllStripes has achieved to date on advancing rare disease research is remarkable and I’m looking forward to utilizing my relationships within the industry and business growth acumen to help drive more value for AllStripes’ clients, and ultimately, those affected by rare diseases.”
To learn more about AllStripes, its partners and its commitment to the rare disease community, please visit allstripes.com.
About AllStripes
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data. AllStripes was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, and a number of angel investors. For more information, visit www.allstripes.com.
